dc.contributor.author |
Rogers, Elaine S |
|
dc.contributor.author |
Sasidharan, Rita |
|
dc.contributor.author |
Sequeira, Graeme M |
|
dc.contributor.author |
Wood, Matthew R |
|
dc.contributor.author |
Bird, Stephen P |
|
dc.contributor.author |
Keogh, Justin WL |
|
dc.contributor.author |
Arroll, Bruce |
|
dc.contributor.author |
Stewart, Joanna |
|
dc.contributor.author |
MacLeod, Roderick D |
|
dc.date.accessioned |
2022-04-25T22:03:01Z |
|
dc.date.available |
2022-04-25T22:03:01Z |
|
dc.date.issued |
2021-10-5 |
|
dc.identifier.citation |
Journal of Health Science and Medical Research 0(0) 05 Oct 2021 |
|
dc.identifier.issn |
2586-9981 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/58771 |
|
dc.description.abstract |
<jats:p>Objective: Cancer cachexia is defined as: a ‘multifactorial syndrome’, and it has been suggested that a multitargeted approach is required in its management. High prevalence is seen within non-small cell lung cancer, and patients may continue to experience cachexia post end of anti-cancer treatment, and in the late/end stage.Material and Methods: Participants who had completed week 20/End of Trial visit in the main Auckland’s Cancer Cachexia evaluating Resistance Training (ACCeRT) study were invited to continue with treatment under compassionate use. Participants could continue with 2.09 g of eicosapentaenoic acid (EPA), 300 mg COX-2 inhibitor (celecoxib), once daily; plus two sessions per week of progressive resistance training (PRT), and 20 g oral essential amino acids (EAA); high in leucine, in a split dose over three days post each session. Data was collected on the acceptability, compliance and adherence to medication/PRT sessions. Secondary endpoints included: change in body weight and fat free mass, handgrip and leg strength, the Functional Assessment of Anorexia/Cachexia Therapy, Multidimensional Fatigue Symptom Inventory-Short Form, World Health Organization Quality of Life — BREF, Glasgow prognostic score, and pro-inflammatory cytokines.Results: All six participants, who completed the main ACCeRT study, opted to continue with compassionate use. Acceptability remained high, with overall compliance to last study/PRT visit of 81.0% for EPA, 98.8% for celecoxib, 78.9% for PRT and 77.2% for EAA. Participants continued to lose body weight and Fat-Free Mass, along with reduced albumin and increased C-Reactive protein levels. Mean time on compassionate study treatment was 78 days, and with a mean overall survival of 257 days (140 + 117).Conclusion: Non-small cell lung cancer (NSCLC) cachectic patients are willing to be enrolled onto a multi-targeted treatment regimen, and may benefit from cachexia symptom management even during their late/refractory stage.</jats:p> |
|
dc.publisher |
Faculty of Medicine Prince of Songkla University |
|
dc.relation.ispartofseries |
Journal of Health Science and Medical Research |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
dc.title |
Acceptability, Compliance, and Safety of Non-small Cell Lung Cancer Cachectic Participants Continuing Compassionate Access in the ACCeRT Clinical Study |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.31584/jhsmr.2021842 |
|
pubs.issue |
0 |
|
pubs.begin-page |
335 |
|
pubs.volume |
0 |
|
dc.date.updated |
2022-03-14T20:25:57Z |
|
dc.rights.holder |
Copyright: JHSMR |
en |
pubs.end-page |
347 |
|
pubs.publication-status |
Published online |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
888191 |
|
dc.identifier.eissn |
2630-0559 |
|
pubs.online-publication-date |
2021-10-5 |
|